IMC-C103C is a highly specialized bispecific T-cell receptor fusion protein designed to target the MAGE-A4 peptide presented by HLA-A*02:01 while simultaneously engaging the CD3 complex on T lymphocytes to facilitate the measurable redirection of polyclonal effector T cells toward antigen-positive tumor cells across various preclinical experimental models.